[go: up one dir, main page]

Sakamoto et al., 1997 - Google Patents

Difference of virus populations in HIV carriers in relation to AZT treatment.

Sakamoto et al., 1997

Document ID
4563029728446098648
Author
Sakamoto T
Wakamiya N
Tochikura A
Tsuchie H
Kurimura T
Sakamoto T
Wakamiya N
Tochikura A
Tsuchie H
Kurimura T
Publication year
Publication venue
International journal of STD & AIDS

External Links

Snippet

To analyse the appearance of AZT-resistant HIV in HIV carriers after AZT treatment and compare the mutations responsible for resistance employing cloned HIV DNA derived from provirus and free virions in plasma, serial blood specimens were taken before and after AZT …
Continue reading at search.ebscohost.com (other versions)

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Similar Documents

Publication Publication Date Title
Kozal et al. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients
Wainberg et al. Development of HIV-1 resistance to (−) 2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex
Gao et al. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2', 3'-dideoxyinosine
Lessells et al. Are subtype differences important in HIV drug resistance?
US7078516B1 (en) Nucleotide sequences derived from the genome of retroviruses of the hiv-1, hiv-2 and siv type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses
Mayers et al. Characterization of HIV isolates arising after prolonged zidovudine therapy
St. Clair et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
Kellam et al. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
Peeters et al. Predominance of subtype A and G HIV type 1 in Nigeria, with geographical differences in their distribution
USRE37918E1 (en) Nucleic acid derivatives
Toure-Kane et al. Sequence Note: Identification of All HIV Type 1 Group M Subtypes in Senegal, a Country with Low and Stable Seroprevalence
Yusa et al. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination
Balotta et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals
NERURKAR et al. Sequence Note: HIV Type 1 Subtype E in Commercial Sex Workers and Injection Drug Users in Southern Vietnam
Wainberg et al. Clinical correlates and molecular basis of HIV drug resistance
Palmer et al. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance
US6531588B1 (en) Methods for HIV sequencing and genotyping
Kuritzkes et al. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
Diaz et al. Divergence of HIV-1 quasispecies in an epidemiologic cluster
Günthard et al. Higher selection pressure from antiretroviral drugs in vivo results in increased evolutionary distance in HIV-1 pol
Murphy et al. Molecular epidemiology of HTLV-II among United States blood donors and intravenous drug users: An age–cohort effect for HTLV-II RFLP type a0
Gurusinghe et al. Reverse transcriptase mutations in sequential HIV‐1 isolates in a patient with AIDS
Reichman et al. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI
Cilla et al. Molecular evidence of homosexual transmission of HIV type 2 in Spain
Sakamoto et al. Difference of virus populations in HIV carriers in relation to AZT treatment.